Valneva SE (NASDAQ:VALN - Get Free Report) shares saw strong trading volume on Thursday . 14,333 shares changed hands during mid-day trading, an increase of 34% from the previous session's volume of 10,711 shares.The stock last traded at $7.37 and had previously closed at $7.57.
Analysts Set New Price Targets
A number of analysts have commented on the stock. Guggenheim cut their price target on shares of Valneva from $18.00 to $17.00 and set a "buy" rating for the company in a research note on Friday, March 22nd. HC Wainwright reiterated a "buy" rating and issued a $26.00 price target on shares of Valneva in a research note on Thursday, March 21st.
Check Out Our Latest Analysis on VALN
Valneva Price Performance
The company has a market capitalization of $517.15 million, a P/E ratio of -4.70 and a beta of 2.22. The company's 50-day moving average price is $7.65 and its two-hundred day moving average price is $9.40. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.65 and a quick ratio of 1.37.
Valneva (NASDAQ:VALN - Get Free Report) last released its quarterly earnings results on Wednesday, March 20th. The company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of $0.20 by ($0.70). Valneva had a negative return on equity of 59.48% and a negative net margin of 65.99%. The business had revenue of $45.12 million for the quarter, compared to the consensus estimate of $45.06 million. As a group, sell-side analysts expect that Valneva SE will post 0.11 EPS for the current year.
About Valneva
(
Get Free Report)
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
Featured Stories
Before you consider Valneva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Valneva wasn't on the list.
While Valneva currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
